Prof. Arie Levine
9
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
33.3%
3 terminated/withdrawn out of 9 trials
66.7%
-19.8% vs industry average
44%
4 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
The Crohn's Disease Exclusion Diet With Partial Enteral Nutrition or Alone in Adult Patients With Crohn's Disease
Role: lead
Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis
Role: lead
Combination of Diet and 5ASA ( 5-aminosalicylic Acid) for Ulcerative Colitis
Role: lead
Diet for Induction and Maintenance of Remission and Re-biosis in Crohn's Disease
Role: lead
Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation
Role: lead
Partial Enteral Nutrition With a Unique Diet vs. Exclusive Enteral Nutrition for the Treatment of Pediatric Crohn's Disease
Role: lead
Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
Role: lead
Use of the Ulcerative Colitis Diet for Induction of Remission
Role: lead
Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure
Role: lead
All 9 trials loaded